OPGN - OpGen Inc Stock Price, Fair Value and News

$0.71-0.36 (-33.64%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

OPGN Price Action

Last 7 days

-20.7%

Last 30 days

-25.5%

Last 90 days

-50.4%

Trailing 12 Months

-71.2%

OPGN RSI Chart

OPGN Valuation

Market Cap

7.1M

Price/Earnings (Trailing)

-0.76

Price/Sales (Trailing)

5.65

EV/EBITDA

-0.65

Price/Free Cashflow

-2.69

OPGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

OPGN Fundamentals

OPGN Revenue

Revenue (TTM)

1.3M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

OPGN Earnings

Earnings (TTM)

-9.4M

Earnings Growth (Yr)

319.82%

Earnings Growth (Qtr)

666.57%

OPGN Profitability

EBT Margin

-742.49%

Return on Equity

-314.74%

Return on Assets

-171.83%

Free Cashflow Yield

-37.19%

OPGN Investor Care

Shares Dilution (1Y)

905.45%

Diluted EPS (TTM)

-19.47

OPGN Alerts

1 major insider buys recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.7M	2.0M	1.3M	0
2023	3.1M	2.8M	3.1M	3.4M
2022	3.9M	4.1M	3.3M	2.6M
2021	4.4M	4.1M	4.2M	4.3M
2020	3.1M	3.3M	3.7M	4.2M
2019	3.1M	3.3M	3.4M	3.5M
2018	1.0M	1.7M	2.3M	2.9M
2017	3.7M	3.2M	3.2M	357.2K
2016	3.8M	4.6M	4.3M	4.0M
2015	3.5M	2.8M	3.0M	3.2M
2014	0	0	0	4.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About OpGen Inc

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÃƒÆ’Ã…Â¡M Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

CEO	Dr. Oliver Schacht Ph.D.
WEBSITE	opgen.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	85

OpGen Inc Frequently Asked Questions

What is the ticker symbol for OpGen Inc? What does OPGN stand for in stocks?

OPGN is the stock ticker symbol of OpGen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of OpGen Inc (OPGN)?

As of Thu Dec 19 2024, market cap of OpGen Inc is 7.15 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OPGN stock?

You can check OPGN's fair value in chart for subscribers.

Is OpGen Inc a good stock to buy?

The fair value guage provides a quick view whether OPGN is over valued or under valued. Whether OpGen Inc is cheap or expensive depends on the assumptions which impact OpGen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OPGN.

What is OpGen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 19 2024, OPGN's PE ratio (Price to Earnings) is -0.76 and Price to Sales (PS) ratio is 5.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OPGN PE ratio will change depending on the future growth rate expectations of investors.